200 mg/m2 melphalan as initial therapy in multiple myeloma:: A key to rapid achievement of complete remission.

被引：0
|
作者：
Powles, R
Sirohi, B
Singhal, S
Goyal, S
Treleaven, J
Lloyd, C
Kulkarni, S
Mehta, J
机构：
[1] Royal Marsden Hosp, Surrey, England
[2] Northwestern Univ, Sch Med, Chicago, IL USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5374
引用
收藏
页码：397B / 397B
页数：1
相关论文
共 50 条
  • [31] 200mg/m2 intravenous melphalan with autologous peripheral blood stem cell transplantation for relapsed multiple myeloma (MM).
    Huang, QA
    Sun, CJ
    Yang, TX
    Wang, WS
    BLOOD, 2002, 100 (11) : 470B - 470B
  • [32] Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
    Jose Lahuerta, Juan
    Victoria Mateos, Maria
    Martinez-Lopez, Joaquin
    Grande, Carlos
    de la Rubia, Javier
    Rosinol, Laura
    Sureda, Anna
    Garcia-Larana, Jose
    Diaz-Mediavilla, Joaquin
    Hernandez-Garcia, Miguel T.
    Carrera, Dolores
    Besalduch, Joan
    de Arriba, Felipe
    Oriol, Albert
    Escoda, Lourdes
    Garcia-Frade, Javier
    Rivas-Gonzalez, Concepcion
    Alegre, Adrian
    Blade, Joan
    San Miguel, Jesus F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1913 - 1920
  • [33] Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study (vol 115, pg 1873, 2010)
    Palumbo, A.
    Bringhen, S.
    Bruno, B.
    BLOOD, 2010, 116 (12) : 2195 - 2195
  • [34] Intensive therapy with high-dose melphalan (MEL) 280 mg/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma.
    Reece, DE
    Vesole, D
    Flomenberg, N
    Badros, A
    Filicko, J
    Herzig, R
    Howard, DS
    Johnson, V
    Meisenberg, B
    Rapoport, A
    Xun, CQ
    Phillips, GL
    BLOOD, 2002, 100 (11) : 432A - 432A
  • [35] A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients
    Palumbo, Antonio
    Cavallo, Federica
    Hardan, Izhar
    Ciccone, Giovannino
    Larocca, Alessandra
    Cavalli, Maide
    Peccatori, Jacopo
    Carella, Angelo Michele
    Brioli, Annamaria
    Cafro, Anna Maria
    Patriarca, Francesca
    Siniscalchi, Agostina
    Pezzatti, Sara
    Crippa, Claudia
    Montefusco, Vittorio
    Levi, Anna
    Ruggeri, Marina
    Caravita, Tommaso
    Ben Yehuda, Dina
    Di Raimondo, Francesco
    Boccadoro, Mario
    BLOOD, 2010, 116 (21) : 1471 - 1471
  • [36] Comparison of 140mg/m2 vs 200mg/m2 Dose of Melphalan in Myeloma Autograft - a Single Centre Experience from Chennai, India
    Kumar, Kishore
    Subash, Chezhian
    BLOOD, 2020, 136
  • [37] 200 mg/m2 melphalan (HDM200) and salvage autotransplantation in myeloma patients relapsing after a preceding autograft.
    Sirohi, B
    Powles, R
    Singhal, S
    Kulkarni, S
    Sankpal, S
    Treleaven, J
    Saso, R
    Horton, C
    Stephens, M
    Mehta, J
    BLOOD, 2002, 100 (11) : 434A - 434A
  • [38] Results of a phase I/II trial adding carmustine (300mg/m2) to melphalan (200mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    Comenzo, RL
    Hassoun, H
    Kewalramani, T
    Klimek, V
    Dhodapkar, M
    Reich, L
    Teruya-Feldstein, J
    Fleisher, M
    Filippa, D
    Nimer, SD
    LEUKEMIA, 2006, 20 (02) : 345 - 349
  • [39] Effect of melphalan 140 mg/m2 vs 200 mg/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience
    Katragadda, Lakshmikanth
    McCullough, Lindsay M.
    Dai, Yunfeng
    Hsu, Jack
    Byrne, Michael
    Hiemenz, John
    May, Stratford
    Cogle, Christopher R.
    Norkin, Maxim
    Brown, Randy A.
    Wingard, John R.
    Chang, Myron
    Moreb, Jan S.
    CLINICAL TRANSPLANTATION, 2016, 30 (08) : 894 - 900
  • [40] Melphalan, prednisone, lenalidomide versus melphalan (200 mg/m2) and autologous transplantation in newly diagnosed myeloma patients: a phase III trial
    Palumbo, A.
    Cavallo, F.
    Nagler, A.
    Gay, F.
    Catalano, L.
    Baraldi, A.
    Galli, M.
    Pescosta, N.
    Cangialosi, C.
    Cascavilla, N.
    Benevolo, G.
    Ria, R.
    Rossi, D.
    Olivero, B.
    Guglielmelli, T.
    Gamberi, B.
    Redoglia, V.
    Di Toritto, T. Caravita
    Di Raimondo, F.
    Boccadoro, M.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S38 - S38
12345